BACKGROUND: Lung cancer is the leading cause of cancer death in most developed countries. Radiotherapy is important in its treatment, with an estimated optimal utilization rate between 45% and 68% at initial diagnosis. The objective of this study was to describe radiotherapy practice for lung cancer in New South Wales (NSW), Australia. METHODS: Patients with lung cancer were identified prospectively from the NSW Central Cancer Registry (CCR) from November 1, 2001 to December 31, 2002. Questionnaires were mailed to diagnosing and treating clinicians to obtain detailed information on diagnosis, staging, referrals, and treatment. The authors describe referral for and receipt of radiotherapy treatment. RESULTS: Of 1812 patients with lung cancer patients who were identified, 943 patients (52%) were referred for radiotherapy, 846 patients (47%) received a radiotherapy questionnaire, and 727 patients (40%) received radiotherapy. Compared with optimal radiotherapy, there was less curative radiotherapy to the primary site (20% actual vs 50% optimal), and there was more palliative radiotherapy to metastatic sites (36% actual vs 11% optimal). The greatest shortfall in radiotherapy use was observed in patients who had limited stage small cell lung cancer (46% actual vs 94% optimal). The use of combined-modality treatment for stage III nonsmall cell lung cancer and for limited stage small cell lung cancer was uncommon. CONCLUSIONS: There is underutilization of radiotherapy for lung cancer in NSW, especially in small cell lung cancer. The use of combined-modality treatment for potentially curable lung cancers is suboptimal. These issues have to be addressed to improve survival and quality of life for patients with lung cancer. Copyright 2009 American Cancer Society.
BACKGROUND:Lung cancer is the leading cause of cancer death in most developed countries. Radiotherapy is important in its treatment, with an estimated optimal utilization rate between 45% and 68% at initial diagnosis. The objective of this study was to describe radiotherapy practice for lung cancer in New South Wales (NSW), Australia. METHODS:Patients with lung cancer were identified prospectively from the NSW Central Cancer Registry (CCR) from November 1, 2001 to December 31, 2002. Questionnaires were mailed to diagnosing and treating clinicians to obtain detailed information on diagnosis, staging, referrals, and treatment. The authors describe referral for and receipt of radiotherapy treatment. RESULTS: Of 1812 patients with lung cancerpatients who were identified, 943 patients (52%) were referred for radiotherapy, 846 patients (47%) received a radiotherapy questionnaire, and 727 patients (40%) received radiotherapy. Compared with optimal radiotherapy, there was less curative radiotherapy to the primary site (20% actual vs 50% optimal), and there was more palliative radiotherapy to metastatic sites (36% actual vs 11% optimal). The greatest shortfall in radiotherapy use was observed in patients who had limited stage small cell lung cancer (46% actual vs 94% optimal). The use of combined-modality treatment for stage III nonsmall cell lung cancer and for limited stage small cell lung cancer was uncommon. CONCLUSIONS: There is underutilization of radiotherapy for lung cancer in NSW, especially in small cell lung cancer. The use of combined-modality treatment for potentially curable lung cancers is suboptimal. These issues have to be addressed to improve survival and quality of life for patients with lung cancer. Copyright 2009 American Cancer Society.
Authors: Bernardo H L Goulart; Carolina M Reyes; Catherine R Fedorenko; David G Mummy; Sacha Satram-Hoang; Lisel M Koepl; David K Blough; Scott D Ramsey Journal: J Oncol Pract Date: 2013-01 Impact factor: 3.840
Authors: Ramie Fathy; Edward Kuan; John Y K Lee; M Sean Grady; Michelle Alonso-Basanta; James N Palmer; Nithin D Adappa; Bert W O'Malley; Jason Brant Journal: J Neurol Surg B Skull Base Date: 2019-10-04
Authors: Stuart Purdie; Nicola Creighton; Kahren Maree White; Deborah Baker; Dan Ewald; Chee Khoon Lee; Alison Lyon; Johnathan Man; David Michail; Alexis Andrew Miller; Lawrence Tan; David Currow; Jane M Young Journal: NPJ Prim Care Respir Med Date: 2019-02-08 Impact factor: 2.871
Authors: Malcolm D Mattes; Jason C Ye; Gabrielle W Peters; Faryal Rizvi; Tarita O Thomas; Ravi A Chandra; Elisabeth Weiss; Stanley I Gutiontov; Sabin B Motwani Journal: J Cancer Educ Date: 2022-03-31 Impact factor: 2.037
Authors: Wee Loon Ong; Norah Finn; Luc Te Marvelde; Colin Hornby; Roger L Milne; Gerard G Hanna; Graham Pitson; Hany Elsaleh; Jeremy L Millar; Farshad Foroudi Journal: J Med Imaging Radiat Oncol Date: 2022-03-31 Impact factor: 1.667
Authors: Bernadette Bea Brown; Jane Young; David P Smith; Andrew B Kneebone; Andrew J Brooks; Miranda Xhilaga; Amanda Dominello; Dianne L O'Connell; Mary Haines Journal: Implement Sci Date: 2014-05-29 Impact factor: 7.327
Authors: Isabel Tovar; Jose Expósito; Javier Jaén; Enrique Alonso; Miguel Martínez; Rosa Guerrero; Juan P Arrebola; Rosario Del Moral Journal: BMC Cancer Date: 2014-09-23 Impact factor: 4.430